Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

136.68
Delayed Data
As of Jan 21
 -2.45 / -1.76%
Today’s Change
117.64
Today|||52-Week Range
189.00
+7.28%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$8.9B

Company Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Contact Information

Jazz Pharmaceuticals Plc
Waterloo Exchange
Dublin Dublin 4
P:(531) 634-7800
Investor Relations:
(531) 634-7892

Employees

Shareholders

Mutual fund holders56.78%
Other institutional39.86%
Individual stakeholders18.45%

Top Executives

Bruce C. CozaddChairman & Chief Executive Officer
Daniel N. SwisherPresident
Christopher John ToveyChief Operating Officer & Executive Vice President
Renée D. GaláChief Financial Officer & Executive Vice President
Robert IannoneChief Medical Officer, EVP-Research & Development